Clinical Trials Directory

Trials / Completed

CompletedNCT01164878

Cholestasis in Extreme Low Birth Weight Infants (ELBW)

Cholestasis in Extreme Low Birth Weight Infants (ELBW) - Possible Influences of a Change in Nutrition Policy

Status
Completed
Phase
Study type
Observational
Enrollment
122 (actual)
Sponsor
Medical University of Vienna · Academic / Other
Sex
All
Age
1 Hour
Healthy volunteers
Not accepted

Summary

Parenteral nutrition associated liver disease (PNALD) in preterm neonates is characterized by early occurrence of intrahepatic cholestasis (parenteral nutrition associated cholestasis (PNAC). Extreme low birth weight infants (ELBW, birth weight \< 1000 g) are at increased risk for development of PNAC. Important factors implicated in the aetiology of PNAC are high caloric parenteral nutrition using amino acids or dextrose, but also intravenous lipids and infections in particular necrotizing enterocolitis (NEC). Due to a change of paradigm a more aggressive nutrition with early use of parenteral amino acids/lipids and early fortification of mothers milk or alternatively high caloric preterm formula is warranted. Accordingly - in line with the existing expert opinion and evidence - the feeding policy at the neonatal care units of our hospital was adapted. Evidence exists that PNAC might be caused by the use of high concentrations of amino acids and lipids in parenteral nutrition. Furthermore NEC is associated with high osmotic feeds. Therefore the incidence of PNAC might be increased directly and indirectly after introducing the new feeding policy. The investigators therefore aim at retrospectively investigating the incidence of PNAC before and after introduction of a feeding policy of "aggressive nutrition" for ELBW infants.

Conditions

Timeline

Start date
2010-01-01
Primary completion
2010-06-01
Completion
2010-07-01
First posted
2010-07-19
Last updated
2016-10-03

Source: ClinicalTrials.gov record NCT01164878. Inclusion in this directory is not an endorsement.